M&A Deal Summary |
|
|---|---|
| Date | 2024-12-17 |
| Target | HUB |
| Sector | Life Science |
| Buyer(s) | MilliporeSigma |
| Deal Type | Add-on Acquisition |
SEARCH BY
MilliporeSigma is a provider of U.S. and Canada life science business of of Merck KGaA.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: Netherlands M&A | 1 of 1 |
| Year: 2024 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-05-22 |
Mirus Bio
Madison, Wisconsin, United States Mirus Bio is a developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery. Mirus Bio's expertise in nucleic acid delivery gives life scientists the most advanced tools for gene expression, biotherapeutic protein production, virus manufacturing, and genome editing. Mirus Bio was founded in 1995 and is based in Madison, Wisconsin. |
Buy | $600M |